CSL Ltd Annual Report 2019

13 Our product portfolio CSL Behring We meet patients’ needs using the latest recombinant and plasma-derived technologies. CSL Behring discovers, develops and delivers the broadest range of products in the industry for treating rare and serious diseases such as haemophilia, von Willebrand disease (vWD), primary immune deficiencies (PI), chronic inflammatory demyelinating polyneuropathy (CIDP), hereditary angioedema (HAE) and inherited respiratory disease. CSL Behring’s products are also used in cardiac surgery, burn treatment and for urgent warfarin reversal. Our therapeutic areas comprise: –– Immunology and Neurology –– Haematology and Thrombosis –– Cardiovascular and Metabolic –– Respiratory –– Transplant Seqirus Our broad range of influenza products meets the needs of different populations around the world. In Australia and the Asia Pacific region, Seqirus is a leading provider of in-licensed vaccines and specialty pharmaceuticals. It is also the world’s only supplier of a unique range of products made in the national interest for the Australian Government, including antivenoms and Q fever vaccine. Influenza Vaccines Egg-based and cell-culture products, seasonal, pre-pandemic and pandemic influenza vaccines Products of National Significance Q fever vaccine and antivenoms for venomous creatures in Australia and other Pacific countries In-licensed Vaccines and Pharmaceuticals For Australia and New Zealand More on CSL.com (Expertise) CSL Limited Annual Report 2019 8 Our Company